NASDAQ:KIN - Kindred Biosciences Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New Kindred Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KIN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KIN

Analyst Price Target is $0.00
This price target is based on 1 analysts offering 12 month price targets for Kindred Biosciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for KIN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Kindred Biosciences. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
2/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
2/17/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/18/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/17/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/16/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/23/2021Alliance Global PartnersDowngradeBuy ➝ NeutralLow
6/17/2021Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
6/17/2021Lake Street CapitalDowngradeBuy ➝ Hold$12.00 ➝ $9.25Low
6/17/2021HC WainwrightDowngradeBuy ➝ Neutral$9.00 ➝ $9.25Low
6/16/2021AegisReiterated RatingBuy ➝ Hold$16.00 ➝ $9.25High
5/12/2021Alliance Global PartnersBoost Price Target$9.25 ➝ $15.25Medium
2/15/2021AegisReiterated RatingBuyMedium
1/26/2021AegisBoost Price TargetBuy$14.00 ➝ $16.00Low
12/21/2020Alliance Global PartnersLower Price Target$10.25 ➝ $9.25Medium
12/1/2020Alliance Global PartnersLower Price TargetBuy$12.50 ➝ $10.25Medium
8/6/2020HC WainwrightReiterated RatingBuy$9.00High
7/29/2020Cantor FitzgeraldLower Price TargetOverweight$25.00 ➝ $11.00High
6/2/2020AegisReiterated RatingBuyMedium
3/17/2020Cantor FitzgeraldReiterated RatingOverweightHigh
3/17/2020Stifel NicolausLower Price TargetBuy$14.00 ➝ $13.00High
3/17/2020HC WainwrightLower Price TargetBuy$16.00 ➝ $9.00High
3/17/2020GuggenheimDowngradeBuy ➝ NeutralHigh
11/13/2019HC WainwrightReiterated RatingBuy$17.50 ➝ $16.00Medium
7/31/2019HC WainwrightReiterated RatingBuy$19.00Medium
7/16/2019B. RileyDowngradeBuy ➝ Neutral$18.00 ➝ $8.50High
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$13.00Medium
5/23/2019GuggenheimInitiated CoverageBuy ➝ Buy$11.00Medium
5/22/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$14.00Medium
4/26/2019Cantor FitzgeraldSet Price TargetBuy$25.00Medium
4/10/2019AegisInitiated CoverageBuy$16.00Low
3/7/2019Lake Street CapitalLower Price TargetBuy$30.00 ➝ $12.00High
3/7/2019HC WainwrightReiterated RatingBuy$19.00High
3/5/2019Cantor FitzgeraldReiterated RatingBuy$25.00Low
1/14/2019Cantor FitzgeraldSet Price TargetBuy$25.00Low
1/14/2019HC WainwrightReiterated RatingBuy$19.00High
12/3/2018Cantor FitzgeraldSet Price TargetBuy$25.00High
11/8/2018B. RileyBoost Price TargetBuy$16.00 ➝ $21.00Medium
11/8/2018HC WainwrightSet Price TargetBuy$19.00High
10/31/2018HC WainwrightSet Price TargetBuy$16.00High
10/31/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Buy$20.00 ➝ $25.00High
9/21/2018Cantor FitzgeraldSet Price TargetBuy$20.00High
9/12/2018Cantor FitzgeraldSet Price TargetBuy$20.00Low
8/13/2018HC WainwrightReiterated RatingBuy$16.00Low
8/9/2018Cantor FitzgeraldReiterated RatingBuy$20.00High
8/7/2018B. RileyBoost Price TargetBuy ➝ Buy$12.50 ➝ $16.00Medium
8/7/2018LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralHigh
7/23/2018Cantor FitzgeraldInitiated CoverageOverweight$20.00Low
7/23/2018Lake Street CapitalInitiated CoverageBuyLow
7/9/2018CL KingUpgradeNeutral ➝ BuyHigh
5/23/2018EuroPacific CanadaInitiated CoverageBuy$16.75Low
5/9/2018HC WainwrightBoost Price TargetBuy$12.00Medium
3/2/2018HC WainwrightSet Price TargetBuy$11.00High
12/27/2017CL KingInitiated CoverageNeutral ➝ NeutralLow
12/22/2017BMO Capital MarketsReiterated RatingHoldHigh
12/15/2017AegisReiterated RatingBuyLow
12/5/2017HC WainwrightSet Price TargetBuy$10.00Low
12/5/2017B. RileySet Price TargetBuy$11.00Low
11/20/2017B. RileyReiterated RatingBuy ➝ Buy$11.00N/A
11/17/2017HC WainwrightInitiated CoverageBuy ➝ Buy$9.50N/A
(Data available from 8/16/2017 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/19/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/18/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/18/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/17/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/17/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/16/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Kindred Biosciences logo
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $9.22
Low: $9.08
High: $9.25

52 Week Range

Now: N/A

Volume

178,496 shs

Average Volume

840,890 shs

Market Capitalization

$420.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Kindred Biosciences?

The following sell-side analysts have issued stock ratings on Kindred Biosciences in the last year: Alliance Global Partners, and StockNews.com.
View the latest analyst ratings for KIN.

What is the current price target for Kindred Biosciences?

0 Wall Street analysts have set twelve-month price targets for Kindred Biosciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Kindred Biosciences in the next year.
View the latest price targets for KIN.

What is the current consensus analyst rating for Kindred Biosciences?

Kindred Biosciences currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KIN, but not buy more shares or sell existing shares.
View the latest ratings for KIN.

What other companies compete with Kindred Biosciences?

How do I contact Kindred Biosciences' investor relations team?

Kindred Biosciences' physical mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company's listed phone number is (650) 701-7901 and its investor relations email address is [email protected] The official website for Kindred Biosciences is kindredbio.com. Learn More about contacing Kindred Biosciences investor relations.